Topical Δ9‐Tetrahydrocannabinol and Aqueous Dynamics in Glaucoma
- 9 August 1981
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 21 (S1) , 467S-471S
- https://doi.org/10.1002/j.1552-4604.1981.tb02626.x
Abstract
Systemic Δ9‐tetrahydrocannabinol (THC), administered either by smoking marihuana or as synthetic THC in soft gelatin capsules, lowers ocular tension in various glaucomas, but at the expense of significant decreases in systolic blood pressure. Topical THC in light mineral oil vehicles, though effective in laboratory animals, was not shown effective in 0.05 and 0.1% topical solutions when administered to six subjects with primary open‐angle glaucoma in a randomized, balanced, double‐masked protocol. Light mineral oil, which has an affinity for corneal epithelium, is an optimum vehicle for administering drugs whose mechanisms of action are systemic rather than local within the eye. Further glaucoma research should therefore proceed with marihuanas containing insignificant levels of THC (less than 0.4%) and with various local delivery systems of the ocular‐active cannabinoid found in Cannabis sativa.Keywords
This publication has 4 references indexed in Scilit:
- Effect of Marihuana on Intraocular and Blood Pressure in GlaucomaOphthalmology, 1980
- Tetrahydrocannabinol effects on elevated blood pressure in humans: William J. Crawford, Howard University Medical School and Hospital, Washington, District of Columbia; Paul C. Alexander; John C. Merritt; Margo J. Thombs; Charles L. CurryPreventive Medicine, 1978
- Cannabinoid penetration and chronic effects in the eyeExperimental Eye Research, 1977
- Mediation of ocular tetrahydrocannabinol effects by adrenergic nervous systemExperimental Eye Research, 1976